275 related articles for article (PubMed ID: 37107587)
1. SODD Promotes Lung Cancer Tumorigenesis by Activating the PDK1/AKT and RAF/MEK/ERK Signaling.
Bao F; An S; Yang Y; Xu TR
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107587
[TBL] [Abstract][Full Text] [Related]
2. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.
Jiang M; Zhou LY; Xu N; An Q
Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884
[TBL] [Abstract][Full Text] [Related]
3. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
[TBL] [Abstract][Full Text] [Related]
4. Silencer of death domains (SODD) inhibits skeletal muscle and kidney enriched inositol 5-phosphatase (SKIP) and regulates phosphoinositide 3-kinase (PI3K)/Akt signaling to the actin cytoskeleton.
Rahman P; Huysmans RD; Wiradjaja F; Gurung R; Ooms LM; Sheffield DA; Dyson JM; Layton MJ; Sriratana A; Takada H; Tiganis T; Mitchell CA
J Biol Chem; 2011 Aug; 286(34):29758-70. PubMed ID: 21712384
[TBL] [Abstract][Full Text] [Related]
5. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
Liu X; Sun L; Zhang S; Zhang S; Li W
J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988
[TBL] [Abstract][Full Text] [Related]
6. [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways].
Liu C; Pei J; Mu X; Yu B; Gong T; Liang W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 May; 38(5):425-431. PubMed ID: 35603651
[TBL] [Abstract][Full Text] [Related]
7. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
8. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
9. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
10. EGF/EGFR Promotes Salivary Adenoid Cystic Carcinoma Cell Malignant Neural Invasion
Ren Y; Hong Y; He W; Liu Y; Chen W; Wen S; Sun M
Curr Cancer Drug Targets; 2022; 22(7):603-616. PubMed ID: 35410600
[TBL] [Abstract][Full Text] [Related]
11. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.
Steelman LS; Abrams SL; Shelton JG; Chappell WH; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
Cell Cycle; 2010 Apr; 9(8):1629-38. PubMed ID: 20372086
[TBL] [Abstract][Full Text] [Related]
12. RUNX2 Plays An Oncogenic Role in Esophageal Carcinoma by Activating the PI3K/AKT and ERK Signaling Pathways.
Lu H; Jiang T; Ren K; Li ZL; Ren J; Wu G; Han X
Cell Physiol Biochem; 2018; 49(1):217-225. PubMed ID: 30138923
[TBL] [Abstract][Full Text] [Related]
13. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
14. MiR-592 Promotes Gastric Cancer Proliferation, Migration, and Invasion Through the PI3K/AKT and MAPK/ERK Signaling Pathways by Targeting Spry2.
He Y; Ge Y; Jiang M; Zhou J; Luo D; Fan H; Shi L; Lin L; Yang L
Cell Physiol Biochem; 2018; 47(4):1465-1481. PubMed ID: 29949784
[TBL] [Abstract][Full Text] [Related]
15. [Study on the Role and Mechanism of METTL3 Mediating the Up-regulation of
m6A Modified Long Non-coding RNA THAP7-AS1 in Promoting the Occurrence of
Lung Cancer].
Zhang Y; Wang Y; Liu M
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):919-933. PubMed ID: 38163978
[TBL] [Abstract][Full Text] [Related]
16. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
17. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.
Yue SJ; Zhang PX; Zhu Y; Li NG; Chen YY; Li JJ; Zhang S; Jin RY; Yan H; Shi XQ; Tang YP; Duan JA
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181779
[TBL] [Abstract][Full Text] [Related]
18. Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway.
Wang Q; Wu H; Wu Q; Zhong S
Drug Dev Res; 2023 Aug; 84(5):907-921. PubMed ID: 37070571
[TBL] [Abstract][Full Text] [Related]
19. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
[TBL] [Abstract][Full Text] [Related]
20. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
